Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia
Wander, Priscilla; Cheung, Laurence C; Pinhanҫos, Sandra S; Jones, Luke; Kerstjens, Mark; Arentsen-Peters, Susan T C J M; Singh, Sajla; Chua, Grace-Alyssa; Castro, Patricia Garrido; Schneider, Pauline; Dolman, M Emmy M; Koopmans, Bianca; Molenaar, Jan J; Pieters, Rob; Zwaan, C Michel; Kotecha, Rishi S; Stam, Ronald W
(2020) Leukemia, volume 34, issue 11, pp. 2898 - 2902
(Article)
Abstract
The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40% [2]. MLL-rearranged infant ALL is both
... read more
clinically and biologically distinct from other childhood ALL subtypes, which is reflected by a unique gene expression profile [3], a remarkably silent mutational landscape [4], and pronounced resistance to currently applied chemotherapeutics [5].
show less
Download/Full Text
An Open Access version of this item is not available due to the copyright policy of the publisher.
Keywords: Animals, Antimetabolites, Antineoplastic/pharmacology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Deoxycytidine/analogs & derivatives, Disease Management, Disease Models, Animal, Drug Evaluation, Preclinical, Gene Rearrangement, Genetic Predisposition to Disease, Humans, Infant, Myeloid-Lymphoid Leukemia Protein/genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
ISSN: 0887-6924
Publisher: Nature Publishing Group
(Peer reviewed)